Blueprint
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 17 April 2018
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
 
 
GlaxoSmithKline plc (the 'Company')
 
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
 
Volume(s)
 
£14.296
 
3,639.339
 
£14.296
 
5,897.033
 
£14.296
 
7.046.678
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
16,583.050
£14.296
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
 
2,125.159
 
£14.296
 
2,031.057
 
£14.296
 
2,793.963
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
6,950.178
£14.296
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
 
534.931
 
£14.296
 
1,523.594
 
£14.296
 
2,121.579
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
4,180.105
£14.296
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
 
3,489.352
 
£14.296
 
2,410.334
 
£14.296
 
3,628.919
 
d)
Aggregated information
 
Aggregated volume Price
 
 
9,528.606
£14.296
 
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
 
2,489.892
 
£14.296
 
3,908.186
 
£14.296
 
3,224.047
 
£14.296
 
3,852.243
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
13,474.367
£14.296
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
 
876.631
£14.296
 
748.274
 
£14.296
 
1,036.207
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
2,661.111
£14.296
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr D S Redfern
 
b)
Position/status
Chief Strategy Officer
 
c)
Initial notification/
amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
 
c)
Price(s) and volume(s)
Price(s)
Volume(s)
 
£14.296
 
1,540.732
 
 
£14.296
 
1,453.809
 
 
£14.296
 
1,915.390
 
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
4,909.931
£14.296
 
 
e)
Date of the transaction
2018-04-12
 
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, HR
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
 
1,939.201
 
£14.296
 
1,603.457
 
£14.296
 
2,171.486
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
5,714.144
£14.296
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
 
1,115.711
 
£14.296
 
1,004.831
 
£14.296
 
1,365.746
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
3,486.288
£14.296
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.296
212.997
£14.296
199.988
£14.296
189.843
d)
Aggregated information
 
Aggregated volume Price
 
 
 
 
602.829
£14.296
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.62
866.909
$40.62
1,399.614
$40.62
1,727.388
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
3,993.911
$40.62
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.62
1,775.668
$40.62
1,559.572
 
d)
Aggregated information
 
Aggregated volume Price
 
 
 
3,335.240
$40.62
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
                       
   
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr H Barron  
b)
Position/status
Chief Scientific Officer and President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.62
3,711.539
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms K Terrell   
b)
Position/status
Chief Digital & Technology Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$40.62
1,432.209
d)
Aggregated information
 
Aggregated volume Price
n/a (single transaction)
 
e)
Date of the transaction
2018-04-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: April 17, 2018 
 
 
 
 
By: VICTORIA WHYTE
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc